Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

10.0%

1 terminated out of 10 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed with results

Key Signals

2 with results89% success

Data Visualizations

Phase Distribution

4Total

P 2 (3)

P 3 (1)

Trial Status

Completed8

Terminated1

Active Not Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT02016924Phase 2Active Not RecruitingPrimary

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT01854775Phase 2CompletedPrimary

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01923311Phase 2TerminatedPrimary

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

NCT02043769Completed

Pediatric Enhanced Surveillance Study

NCT02027441Completed

Enhanced Prevention in Couples: Feasibility Study #2

NCT02027714Completed

Enhanced HIV Prevention in Couples: Feasibility Study #1

NCT01997359Completed

Multi-level Determinants of Starting ART Late: Aim 3

NCT01997346Completed

Multi-level Determinants of Starting ART Late: Aim 2

NCT02027519Completed

Enhanced HIV Prevention in Couples: Feasibility Study #3